Alnylam Pharmaceuticals
ALNY
#568
Rank
S$55.80 B
Marketcap
S$420.79
Share price
-1.09%
Change (1 day)
26.56%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): S$0.11

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is S$0.11. In 2023 the company made an earnings per share (EPS) of S-$4.47 an increase over its 2022 EPS that were of S-$11.76.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$0.11
2023S-$4.47-62%
2022S-$11.7629.03%
2021S-$9.11-3.36%
2020S-$9.43-8.48%
2019S-$10.307.67%
2018S-$9.5739.74%
2017S-$6.8512.94%
2016S-$6.0638.84%
2015S-$4.37-32.88%
2014S-$6.50259.44%
2013S-$1.81-31.25%
2012S-$2.63

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
S$9.31 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
S$2.61 2,194.62%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
S$54.57 47,811.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
S-$3.47-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
S-$0.92-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
S-$0.30-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
S$1.57 1,277.78%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
S-$1.58-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA